FDA seems increasingly interested in tinkering with the GDUFA fee structure in its next cycle to prevent manufacturers from being forced to pay facility fees for years while waiting for their first ANDA approval.
During a June 15 public hearing on reauthorization of the generic drug user fee program, trade groups representing manufacturers again complained that the facility fees can in some cases are...